To evaluate safety and performance of the BioMimeâ?¢ Morph Sirolimus-Eluting Coronary Stent Systems in the treatment of patients with coronary artery blockage.
Phase 4
Completed
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Registration Number
- CTRI/2018/01/011230
- Lead Sponsor
- Meril Life Sciences Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 362
Inclusion Criteria
1. Patients who have been treated with BioMime• Morph.
2. Patients who are contactable, willing to participate will be taken into the study by signing voluntary informed consent form.
Exclusion Criteria
1. There are no exclusion criteria for this study.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of sirolimus in coronary artery disease treatment?
How does the BioMime Morph stent compare to other drug-eluting stents in atherosclerosis management?
What biomarkers are used to predict response to sirolimus-eluting stents in I251 patients?
What are the potential adverse events associated with BioMime Morph stent systems and their management?
Are there any combination therapies involving sirolimus-eluting stents for coronary artery lesions?